In vitro development of haemopoietic progenitors in myelodysplastic syndromes (MDS) TO 
THE EDITOR
In an attempt to explain the presence of normal to increased numbers of marrow normoblasts in patients with myelodysplastic syndromes (MDS) despite low BFU-E numbers in vitro, Brada et al 1 have suggested that MDS progenitors may be defective in their ability to proliferate, but not differentiate. However, for a similar phenomenon to exist in vivo, a substantial increase in the erythroid progenitor compartment would be required to maintain normal numbers of marrow normoblasts. Studies on BFU-E and CFU-E development in many MDS patients are characterised by decreased erythroid growth rather than an increase in numbers of small-sized haemoglobinised colonies, 2 and this argues against an expansion of the erythroid progenitor compartment in MDS. Despite low numbers of BFU-E/CFU-E and proliferative defects in these cells, normal levels of normoblasts may be achieved if there is an increase in the rate of maturation of erythroid progenitors/precursors. Although an increase in maturation is unlikely in MDS, 3 rates of maturation have not been examined in the studies by Brada et al, and the data they have presented are insufficient to justify their conclusions. Furthermore, in the absence of ferrokinetic studies and measurements of erythroid mass in individual patients in the study, it is difficult to establish whether impaired proliferation of erythroid progenitors/precursors observed in vitro, correlates with behaviour of these cells in vivo.
Secondly, it is not clear why candidate progenitor cells (CD34
were separated following overnight incubation of marrow mononuclear cells (MNC) in 10% fetal bovine serum, rather than from freshly isolated MNC. We have shown previously that stroma-free suspension cultures of marrow MNC in human Dexter culture medium (12.5% fetal bovine serum and 12.5% horse serum) are characterised by an increase in BFU-E numbers over baseline values at 4 or 8 h of culture, followed by a decline at 18 h. 4 Cytosine arabinosidebased suicide assays in these cultures indicated that the increase in BFU-E was a result of cellular proliferation. BFU-E recovered at 4 or 8 h (Figure 1b) were larger and better haemoglobinised than those detected in assays from fresh MNC (Figure 1a) , suggesting that the differentiation/maturation potential of BFU-E was altered in suspension culture. BFU-E were also detected to cycle in medium containing lower amounts of serum (10%, 15% and 20%), suggesting that factors in serum and/or those produced within the MNC microen-
Figure 1
Morphology of BFU-E during the phase of increase in suspension cultures of normal marrow mononuclear cells (MNC) (b), compared to bursts produced prior to suspension culture (a). BFU-E detected after suspension culture were larger and better haemoglobinised than in assays performed using fresh MNC. vironment may alter the functional properties of BFU-E during incubation at 37°C. When MNC from MDS marrow and marrow harvested from patients after recovery from chemotherapy were incubated in suspension cultures, an early decline in BFU-E numbers was observed. 5 Further studies on the clonal origin of cells developing in semi-solid assays are required to determine whether the developmental defect in suspension cultures affects normal or abnormal BFU-E. Nevertheless, our experiments indicate that pre-incubation of MNC during isolation of CD34 
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One of the main characteristics of myelodysplasia is anemia, despite the fact that a normal or increased number of normoblasts are observed in the bone marrow. To study whether this discrepancy might be in part due to a defect in the proliferation and differentiation of erythroid progenitors, an in vitro culture system was used with CD34 + /CD36 − sorted bone marrow cells of myelodysplasia patients. Selection of this subpopulation of hematopoietic stem cells provides the opportunity to enrich for the BFU-E colony forming cells. 1 Moreover, the CD34
− sorted bone marrow cells can selectively differentiate in the in vitro suspension culture assay along the erythroid lineage in the presence of erythropoietin and mast cell growth factor. 1 By using these assays we demonstrated a strong impairment in the proliferative response of CD34
− sorted bone marrow cells of myelodysplasia patients. 2, 3 In contrast, the sorted CD34 + /CD36 − bone marrow cells differentiated in the in vitro suspension culture assay to a certain degree along the erythroid lineage. 3 These results demonstrate that by using highly selective cell populations, important information can be obtained with regard to the proliferative and differentiative capacity of erythroid progenitors of myelodysplasia patients. However, these data were not of predictive value for the in vivo erythroid kinetic data measured with ferrokinetic studies.
